Lilly Sales Swing Back As Pandemic, Loss Of Exclusivity Pressures Recede
Diabetes, Immunology, Oncology Lead 28% Sales Jump
Executive Summary
The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.
You may also be interested in...
English Funding Nod For Lilly’s Diabetes GLP-1 Mounjaro, Roche’s Cancer MAb Columvi
Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.
Price Negotiation And The GLP1 Class: Trulicity Lucky To Be A BLA
The inaugural class of drugs subject to the new US Medicare price negotiation process includes four antidiabetics. But none are from the biggest and fastest growing class – thanks to few technicalities in how the law works.
Stock Watch: Lilly And Novo Provide An Earnings Season Crescendo
The commercial and clinical successes of Lilly and Novo's respective GLP-1 receptor agonists provided an explosive finale to the second-quarter earnings season but also raised questions on reimbursement.